Skip to content

Medical Tai Chi Exercise Healing in Treating mCRC Patients

A Single-Arm, Prospective, Exploratory Study to Evaluate Feasibility and Effect of Medical Tai Chi Exercise Healing in Treating mCRC Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06104267
Enrollment
30
Registered
2023-10-27
Start date
2023-09-01
Completion date
2024-12-31
Last updated
2023-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Brief summary

As a traditional martial art in China, Tai Chi Chuan has excellent health benefits along with its combat function.Studies have shown that Tai Chi as an exercise prescription can significantly reduce the incidence of cancer, but the complexity of Tai Chi Chuan routines, poor disease targeting, and the lack of traditional internal mental and physical training method limit the healing of tumours and other diseases. For this reason, we have established the Medical Tai Chi Exercise Healing System(MTCEH), which integrates Tai Chi exercise, traditional Chinese internal mental and physical training method, rehabilitation medicine and sports medicine methods, on the basis of evidence-based medicine and with the aim of targeting different tumour treatments. With the characteristics of easily learning, internal and external training, and individualised treatment of tumours, this series of routines effectively combines traditional oriental Tai Chi martial arts with tumour treatment, which opens up a beautiful and mysterious oriental healing journey for integrative medicine.

Interventions

BEHAVIORAL7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients

The programme is based on the 7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients that lasted 60 minutes three times a week for eight weeks and is led by a Tai Chi instructor with more than 5 years of teaching experience. Each session included a warm-up, movement instruction, breathing techniques, and relaxation. To ensure that each participant is proficient in Tai Chi, they will take at least 2 sessions of 60-minute Tai Chi training before the start of the intervention, until they are able to perform all Tai Chi movements correctly and successfully, and record a video to be used in software for practice at home. The enrolled patients, Tai Chi instructors and relevant staff of the subject group set up a WeChat group, and the enrolled patients, outside of the prescribed practice time each week, can practice at home or outdoors by themselves. They can send the video of the practice to the WeChat group.

Sponsors

SIR RUNRUN Hospital
CollaboratorUNKNOWN
The First Affiliated Hospital with Nanjing Medical University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Histological or cytological documentation of adenocarcinoma of the colon or rectum. 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. 3. Life expectancy of at least 6 months. 4. Adequate bone marrow, liver, cardiac and renal function as assessed by the laboratory required by protocol(ALT/AST≤2.5×UNL or ≤5×UNL with liver metastasis,TBIL≤2.5×UNL,Cr≤1.5×UNL,WBC≥3×109/L,NE≥1.5×109/L,PLT≥80×109/L,Hb≥90g/L,PT-INR/APTT \<1.5UNL; LVEF≥ 50%). 5. Subjects must complete the treatment and follow-up on schedule according to the research plan.

Exclusion criteria

1. Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors \[Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)\]. 2. Any serious or unstable medical condition、mental illness or known active alcohol or drug abuse or dependence. 3. Unhealed surgical wounds and intolerance 4. Extreme fatigue, anemia (\<80 g/L) or dystaxia 5. toxicity grade ≥III in chemoradiotherapy or targeted therapy (NCI-CTCAE 5.0), or severe intolerance 6. exercise contraindications for patients with cardiovascular diseases or pulmonary diseases (referring to the Chinese Guideline for Cardiac Rehabilitation and Secondary Prevention \[edition 2018\] and Evidence-based Practice Guidelines for Clinical Rehabilitation of Chronic obstructive Pulmonary Disease \[edition 2021\]); uncontrolled unstable angina, diastolic dysfunction grade IV, uncontrolled severe arrhythmia, uncontrolled hypertension; 7. high fever, serious infection, dyscrasia, multiple organ failure, or incapability to cooperate 8. thrombosis in the active phase 9. For female subjects: they should be surgical sterilized, postmenopausal patients, or agree to use a medically approved contraceptive method during the study treatment period and within 6 months after the end of the study treatment period; The serum or urine pregnancy test must be negative within 7 days before enrollment and must be non lactating. Male subjects: patients who agree to use a medically approved contraceptive method during the study treatment period and within 6 months after the end of the study treatment period. 10. other conditions confirmed by the multidisciplinary cancer rehabilitation team.

Design outcomes

Primary

MeasureTime frameDescription
Adherence ratespost 8-week interventionThe adherence rates will be measured by the number of tai chi sessions performed divided by the total possible tai chi sessions

Secondary

MeasureTime frame
the Brief Fatigue Inventory (BFI)post 8-week intervention
the Pittsburgh Sleep Quality Index (PSQI)post 8-week intervention
EORTC - Quality of Lifepost 8-week intervention
self-rating anxiety scale(SAS)post 8-week intervention
self-rating depression scale(SDS)post 8-week intervention

Countries

China

Contacts

Primary ContactYanhong Gu
guluer@163.com+8618915594572
Backup ContactTianzhu Qiu
tianzhu_qiu@163.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026